We propose that response to combination endocrine/EGFRi therapies in ER+ luminal cancers may improve long-term survival in patients whose tumors have been preselected [42] for presence of a luminobasal subpopulation based on ER/PR, CK5 and EGFR biomarker expression. The gene discussed is ESR1; the disease is cancer.